VPS36 inhibitors are a class of chemical compounds that specifically target the VPS36 protein, an essential component of the Endosomal Sorting Complex Required for Transport II (ESCRT-II). VPS36 plays a critical role in the endosomal-lysosomal pathway by facilitating the sorting of ubiquitinated membrane proteins into multivesicular bodies. This process is vital for various cellular functions, including signal transduction, receptor downregulation, and membrane protein turnover. VPS36 contains a GLUE (GRAM-like Ubiquitin-binding in EAP45) domain, which enables it to bind ubiquitin and phosphoinositide lipids, thereby recruiting other ESCRT components to endosomal membranes. By interacting with VPS36, inhibitors can disrupt these fundamental cellular processes, offering insights into the mechanisms of vesicular trafficking and membrane dynamics.
Chemically, VPS36 inhibitors are designed to interfere with the functional domains of the VPS36 protein, such as the GLUE domain, to prevent its interaction with ubiquitin or other ESCRT components. These inhibitors may consist of small molecules, peptides, or other biologically active compounds that exhibit high specificity and affinity for VPS36. The development of VPS36 inhibitors often involves structure-based drug design, computational modeling, and high-throughput screening techniques to identify compounds that effectively bind to VPS36 and inhibit its function. By modulating the activity of VPS36, researchers can study the protein's role in cellular pathways, understand the consequences of impaired endosomal sorting, and explore the broader implications of ESCRT-mediated processes in cell biology.
SEE ALSO...
Items 191 to 11 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|